Emmessar Biotech & Nutrition Ltd
Emmessar Biotech & Nutrition Ltd (EMMESSA) last traded at ₹24.2, a market capitalisation of ₹12.1 crore, on a P/E of 31.1. Over the past 52 weeks the stock has ranged between ₹18.4 and ₹42.8. Emmessar Biotech & Nutrition Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0.06 crore and net profit of ₹0.13 crore. Figures are as of 25 Aug 2026 and are not real time.
Emmessar Biotech & Nutrition Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Emmessar Biotech & Nutrition Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.06 cr, down 33.3% from ₹0.09 cr a year earlier. Net profit was ₹0.13 cr, down 23.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.34 | 0.1 | 0.1 | 0.09 | 0.09 | 0.09 | 0.09 | 0.06 |
| Expenses | 0.42 | 0.38 | 0.43 | 0.36 | 0.46 | 0.43 | 0.46 | 0.41 |
| Operating profit | -0.08 | -0.28 | -0.33 | -0.27 | -0.37 | -0.34 | -0.37 | -0.35 |
| OPM % | -23.53% | -280.00% | -330.00% | -300.00% | -411.11% | -377.78% | -411.11% | -583.33% |
| Other income | 0.51 | 0.43 | 0.61 | 0.53 | 0.54 | 0.49 | 0.47 | 0.54 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| Profit before tax | 0.41 | 0.13 | 0.26 | 0.24 | 0.14 | 0.12 | 0.07 | 0.17 |
| Tax % | 31.71% | 84.62% | 126.92% | 25.00% | 21.43% | 8.33% | 57.14% | 17.65% |
| Net profit | 0.28 | 0.02 | -0.07 | 0.17 | 0.11 | 0.12 | 0.03 | 0.13 |
| EPS (₹) | 0.56 | 0.04 | -0.14 | 0.34 | 0.22 | 0.24 | 0.06 | 0.26 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Emmessar Biotech & Nutrition Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 | 0.33 |
| Operating profit | 0.84 | -0.9 | -0.69 | -1.08 | -0.95 | -1.36 | -1.43 |
| OPM % | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -367.57% | -433.33% |
| Net profit | 1.45 | 0.48 | 0.5 | 0.75 | 0.32 | 0.44 | 0.39 |
| EPS (₹) | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.88 | 0.78 |
TTM is the trailing twelve months to the most recent quarter.
Emmessar Biotech & Nutrition Ltd growth and returns
- 10 Years
- -15%
- 5 Years
- -44%
- 3 Years
- -29%
- TTM
- -48%
- 10 Years
- 14%
- 5 Years
- -21%
- 3 Years
- -4%
- TTM
- -3%
- 10 Years
- 3%
- 5 Years
- -6%
- 3 Years
- -1%
- 1 Year
- -14%
- 10 Years
- 15%
- 5 Years
- 7%
- 3 Years
- 7%
- Last Year
- 6%
Emmessar Biotech & Nutrition Ltd shareholding pattern
Promoters held 59.53% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.19%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% | 59.53% |
| DIIs | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| Public | 40.27% | 40.28% | 40.27% | 40.28% | 40.28% | 40.27% | 40.26% | 40.26% |
| No. of shareholders | 6,936 | 7,186 | 7,180 | 7,173 | 7,350 | 7,244 | 7,172 | 7,136 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Emmessar Biotech & Nutrition Ltd corporate filings
- Newapaper AddCompany Updatelow impact
Cruxal's analysis: The company has released a routine newspaper advertisement as part of its statutory…
Read the full analysis - Board Meeting Outcome for For Unaudited Financial Results For The Quarter Ending June 30, 2026Board Meetingmedium impact
Cruxal's analysis: Emmessar Biotech & Nutrition Limited reported a net profit of 13.15 lakh for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Emmessar Biotech & Nutrition Ltd
Cruxal reads every Emmessar Biotech & Nutrition Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.